Alliance for Pandemic Preparedness

May 7, 2021

Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2  Variant Vaccine Booster

Category:

Topic:

Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] Preliminary results from a clinical trial (N=80) of a modified Moderna  mRNA COVID-19 vaccine administered as a booster 6 months after the two-dose vaccine series  induced increases in antibody neutralization titers to the wild type and variant strains B.1.351 and  P.1. The authors note that these results demonstrate the ability of a third vaccine dose to boost  immunity to titers that may exceed peak titers following the primary two-dose vaccination series  against both wild-type virus and variants.  

Wu et al. (May 6, 2021). Preliminary Analysis of Safety and Immunogenicity of a SARS-CoV-2  Variant Vaccine Booster. Pre-print downloaded May 7 from  https://doi.org/10.1101/2021.05.05.21256716